MET and lung adenocarcinoma: For example, for the tyrosine kinase inhibitor (TKI) crizotinib a FISH established cutoff of 10 copies of the MET gene in lung adenocarcinoma has been suggested [16], while only very limited data on the response related to low-level (4–9 copies) and high-level (≥ 10 copies) amplification are presently available [17, 18].